Vol 16, No 3 (2014)


Press Release. New data show Giotrif® (afatinib) provided more than one year additional survival for patients with lung cancer associated with the most common type of EGFR mutation (del19) compared to chemotherapy

- -.


Пациенты с немелкоклеточным раком легкого (НМРЛ) и мутацией EGFR del19 жили в среднем более чем на 1 год дольше (медиана общей выживаемости - ОВ увеличивалась более чем на 1 год), если лечение начинали с препарата афатиниб вместо стандартной ХТ.Афатиниб - первый препарат, показавший преимущество в отношении ОВ больных НМРЛ с определенными типами мутаций EGFR
Journal of Modern Oncology. 2014;16(3):6
pages 6 views

Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women

Jackisch C., Llombart-Cussac A.


Breast cancer (BC) is the most common cancer in women in the world. HER2-negative hormone receptor-positive BC is present in 70% of all cases of BC. A key role in the treatment of this type of BC plays an endocrine therapy, effective at disease progression as well. This article presents and discusses data on modern treatment options of HER2-negative hormone receptor-positive advanced BC, including combined endocrine and targeted therapy with mTOR inhibitor everolimus.
Journal of Modern Oncology. 2014;16(3):16-21
pages 16-21 views

Personalized approach to HER2-positive advanced breast cancertherapy

Stenina M.B.


Anti-HER2 therapy is a standard component of drug therapy for HER2-positive breast cancer. The advent of new drugs of this group creates additional possibilities for treatment and necessitates for creating an algorithm according to the characteristics of each patient. We analyzed possible therapeutic options concerning international guidelines for treating HER2-positive advanced breast cancer.
Journal of Modern Oncology. 2014;16(3):21-26
pages 21-26 views

Skin sparing mastectomy

Ovchinnikov M.V., Egorov Y.S.


The review article deals with the historical evolution of breast surgery and shows the modern view on breast reconstruction during mastectomy surgery. Numerous studies, concerning the radicality of this surgery, demonstrate the safety of the procedure in strictly selected patients. We have been describing the main variants of surgical approaches and modern understanding of nipple-areolar complex perfusion in the article.
Journal of Modern Oncology. 2014;16(3):27-32
pages 27-32 views

Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial

Ahmetzanov F.S., Ahmetzanova F.F.


The article deals with the results of the administration of new cytostatic - eribulin (Halaven). In EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) phase III clinical study, Halaven had been administrated to 6 patients (between 6 and 35 cycles), at that, partial tumor regression was observed in 3 patients and other 3 patients achieved stabilization. Median progression-free survival (PFS) was 15,3 months and median duration of response (DOR) was 13 months in eribulin group, in group of treatment of physician's choice - median PFS was 5,3 and median DOR was 3,3 months. This article demonstrates 3 clinical cases. The authors concluded that eribulin showed high effectiveness and meaningful improvement in overall survival, maintaining the high quality of life.
Journal of Modern Oncology. 2014;16(3):33-38
pages 33-38 views

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment

Besova N.S.


The main method of treatment patients with disseminated gastric cancer is drug therapy. Trastuzumab has proven its efficacy in therapyHER2-positive gastric cancer in combination with chemotherapy. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival and, therefore, is required to treat these patients.
Journal of Modern Oncology. 2014;16(3):39-42
pages 39-42 views

Avastin in clinical chemotherapy of malignant tumors

Gorbunova V.A.


Avastin (bevacizumab) is a humanized monoclonal antibody with evident antiangiogenic activity, which blocks vessel endothelial growth factor (VEGF) and prevent its binding with receptors. Chronologically Avastin was among the first (second after trastuzumab) targeted agents approved for clinical practice. Also it is the only targeted agent used in the main malignant solid tumor types: metastatic colorectal cancer, locally recurrent or metastatic breast cancer, metastatic or recurrent nonsquamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, glioblastoma (stage IV glioma according to WHO classification) and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Therefore Avastin can be defined today as the first and the best, because not one targeted agent has so wide clinical use and indications in practical oncology and moreover practically there were no ineffective clinical trials with Avastin. Also it is necessary to mention that large clinical experience with Avastin demonstrates comparative safety of the agent in different patient’s subgroups and populations.
Journal of Modern Oncology. 2014;16(3):45-51
pages 45-51 views

Bevacizumab in advanced ovarian cancer: when, what for and why?

Tjulandina A.S.


Treatment of advanced ovarian cancer remains a complex problem, which generates interest in researchers. Since there have been no changes in standard cytostatic treatment for last 20 years, addition of targeted drugs to the first-line therapy is considered to be a perspective approach. Currently the most examined group of targeted drugs in ovarian cancer is anti-angiogenic agents, with bevacizumab being one of the most intensively studied drugs in the field. This article analyses the results of the recent studies and the perspectives for the use of bevacizumab in advanced ovarian cancer.
Journal of Modern Oncology. 2014;16(3):52-57
pages 52-57 views

Modern options in personalized therapy of metastatic cutaneous melanoma

Protsenko S.A., Novik A.V., Akhaeva Z.Y., Zhabina A.S., Imyanitov E.N., Semenova A.I.


A great progress was recently achieved in metastatic melanoma therapy. New targeted therapies allow high efficacy expectations for personalized treatment approaches. BRAF-inhibitors significantly increase time to progression, overall survival and response rate in malignant melanoma patients. Vemurafenib is the first registered in Russia drug of this type. Current clinical data review on vemurafenib is presented in this paper.
Journal of Modern Oncology. 2014;16(3):57-64
pages 57-64 views

Current algorhytm of screening and early diagnosis of hepatocellular carcinoma

Tikhonov I.N., Pavlov C.S., Mayevskaya M.V., Ivashkin V.T.


The article presents the current possibilities for screening and early diagnosis of hepatocellular carcinoma with imaging techniques, non-invasive serological and immunohistochemical markers, as well as indications and accuracy for morphological study of focal lesions of the liver in patients of risk group.
Journal of Modern Oncology. 2014;16(3):65-74
pages 65-74 views

Targeted therapy for metastatic renal cell carcinoma

Porta C., Tsimafeyev I.V.


Seven small molecular weight targeted agents have been approved for the treatment of metastatic renal cell carcinoma (mRCC), includ-ing the humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (used in combination with interferon [IFN]-a); the multi-targeted receptor tyrosine kinase inhibitors (TKIs) sunitinib, pazopanib, axitinib and sorafenib; and the mammalian target of rapamycin inhibitors (mTORIs) everolimus and temsirolimus. According to the results of comparative clinical trials of sunitinib and pazopanib (COMPARZ and PISCES), pazopanib has more preferable safety profile due to elimination of the risk of hepatic complications. However, 20-25% of patients do not respond to the first-line therapy. The treatment strategy for this group of patients is to select optimal treatment sequence. The robust clinical data confirm the advantage of consecutive usage of targeted agents in patients with mRCC, explaining the improved response with lack of cross-resistance. Currently, everolimus is an optimal choice in the second-line targeted therapy for mRCC since it has high-level evidence of its efficacy and at the same time it allows to overcome resistance to the anti-angiogenic therapy. Currently, there are no sufficient data on the effectiveness of the targeted agents in the third-line setting.
Journal of Modern Oncology. 2014;16(3):75-80
pages 75-80 views

Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib

Smolin A.V., Gorbacheva A.V.


Background. A key challenge in the treatment of advanced non-small-cell lung cancer (NSCLC) is improving outcomes for patients infirst, second line and maintenance therapy. We analyzed group of patients with progression free survival 6 month in order to elicit predic-tors of long response to the therapy with erlotinib.Methods. Between 2005 and 2013, we collect demographic data about 69 patients with NSCLC with PFS more than 6 month. In first linehave received 27 pts, second line - 36 pts and maintenance therapy - 6 pts. In most cases, data about mutation of EGFR was available.Results. We found possible correlation between level of response and duration of PFS. Duration of PFS in group with complete responsewas - 14,9 month, partial response - 12,9 month, stable disease - 12 month. Cohort of patients with the best response and longest PFSconsist of those with EGFR mutations, women and never or light smokers. We found 6 patients without EGFR mutation, in 5 of them thebest response was durable stable disease and in one - partial response.Conclusion. There are data supporting strong correlation between EGFR mutation status and objective response and duration of PFS inpatients treated with erlotinib. Patient without EGFR mutation have a real chance to reach long lasting stable disease in maintenance andsecond line therapy. Simple clinical characteristic, such as smoking status, gender and tumor histology can be used for selection patientsfor therapy with erlotinib.
Journal of Modern Oncology. 2014;16(3):81-86
pages 81-86 views

Prospects for revision of the histological classification of neuroendocrine tumorsBased on the materials of 11-th Annual European Neuroendocrine Tumor Society Conference

Gurevich L.E., Delectorskaya V.V.


The revision of the classification of neuroendocrine tumors (NETs), such as gastrointestinal (GI), pancreatic (PETs) and lungs tumors, according to the new approaches to determine the tumor grade (Grade) is becoming increasingly important. All these tumors differ according to the clinical course and response to different therapeutic regimens. 11-th annual European Neuroendocrine Tumor Society Conference (ENETS), which took place on 5-7 March 2014 in Barcelona (Spain), had been devoted to the choice of new thresholds of mitotic index and Ki-67 proliferation index to make changes in the gradation system of GI NETs and PETs and to divide the previous groups G2 and G3 into the subunits. Besides, it was suggested to unify the lung and GI NETs terminology and to divide lung NETs in to the G1, G2 and G3 groups, according to the threshold levels of mitotic index and Ki-67 proliferation index, concerning the localization of these tumors.
Journal of Modern Oncology. 2014;16(3):86-90
pages 86-90 views

Vulvar Langerhans cell histiocytosis: case report

Poddubnaya I.V., Razumova E.L., Kizhaev Y.E., Ukolova E.A., Teterin K.A.


We report a 33-year-old female patient with primary isolated malignant vulvar Langerhans cell histiocytosis (LCH). The effectiveness of hemivulvectomy with adjuvant EBRT and chemotherapy is presented. Adequate tissue excision followed by histological study with immunohistochemistry was of critical importance for the diagnosis in our case. Unified management recommendations with multidisciplinary approach are required.
Journal of Modern Oncology. 2014;16(3):90-92
pages 90-92 views

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer

Gridneva Y.V., Matveev V.B., Kupchan D.Z., Kalinin S.A., Peters M.V.


In a recent randomized, double-blind, phase III clinical trials among patients with metastatic castration-resistant prostate cancer (CRPC) progressing on androgen-deprivation therapy or after docetaxel chemotherapy, abiraterone acetate was shown to significantly prolong radiographic progression free survival and overall survival compared with prednisone alone, even in symptomatic patients and patients having visceral metastases and high level of prostate specific antigen at baseline. Here we present our own experience with abiraterone acetate in patients who represent negative prognostic factors of castration-resistant prostate cancer outside of clinical trials. 25 metastatic CRPC patients were treated with abiraterone acetate from 2012 to 2014.
Journal of Modern Oncology. 2014;16(3):94-96
pages 94-96 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies